
Web Release Date: April 21,
Biocatalytic Racemization of Aliphatic, Arylaliphatic, and
Aromatic
-Hydroxycarboxylic Acids








and
Department of Chemistry, Organic and Bioorganic Chemistry, University of Graz, Heinrichstrasse 28, A-8010 Graz, Austria, and BASF-AG, GVF/E-B9, D-67056 Ludwigshafen, Germany
Received January 25, 2005
Abstract:
![]() |
-hydroxycarboxylic
acids was accomplished by using whole resting cells of a range of Lactobacillus spp. The mild
(physiological) reaction conditions ensured an essentially "clean" isomerization in the absence of
side reactions, such as elimination or decomposition. Whereas straight-chain aliphatic 2-hydroxycarboxylic acids were racemized with excellent rates (up to 85% relative to lactate), steric hindrance
was observed for branched-chain analogues. Good rates were observed for aryl-alkyl derivatives,
such as 3-phenyllactic acid (up to 59%) and 4-phenyl-2-hydroxybutanoic acid (up to 47%). In addition,
also mandelate and its o-chloro analogue were accepted at a fair rate (45%). This biocatalytic
racemization represents an important tool for the deracemization of a number of pharmaceutically
important building blocks.
Racemization is an irreversible entropy-driven isomerization reaction leading to a loss of enantiomeric purity,1
discovered by Pasteur in 1853. Since it usually goes in
hand with a loss of the "chiral value" of materials, it has
been generally considered as an unwanted side reaction
rather than a synthetically useful transformation. As a
consequence, the controlled racemization of organic
compounds has been scarcely studied.1,2 It was only
recently that the need for "clean" racemization protocols
had been recognized in particular due to the increasing
demand for so-called deracemization processes, which
allow the complete transformation of a racemate into a
single stereoisomeric product in 100% theoretical yield.3,4
Detailed analysis of the (chemical) racemization protocols published so far2 reveals that the general reaction
conditions employed for racemization favor strongly
acidic or basic media, which are incompatible with the
presence of a stereoselective (catalytic) in situ transformation. As a consequence, traditional (chemical) protocols
for racemization are thus of limited use for dynamic
kinetic resolutions.5-8
During our studies directed toward the deracemization
of
-hydroxycarboxylic acids by coupling lipase-catalyzed
acyl-transfer to racemization of the nonreacted substrate
enantiomer using mandelate racemase [EC 5.1.2.2]10 we
encountered a stringent substrate limitation for the latter
enzyme: Although mandelate racemase was very tolerant toward various
,
-unsaturated
-hydroxycarboxylic
acids,11 saturated (aliphatic) substrate analogues were
not accepted at all. The latter fact can be explained by
the lack of resonance stabilization of the corresponding
enolate intermediate within the active site of the enzyme.12,13
-hydroxycarboxylic acids, which are lacking the minimum structural requirements of mandelate racemase, i.e., at least
one C=C bond in the
,
-position, a matching isomerase/racemase enzyme was required.
Due to the fact that the vast majority of biochemical
processes are stereospecific, Nature has faced little need
for racemization and, as a consequence, "racemases" are
a small group of enzymes, which have been biochemically
classified as subgroup [EC 5.1.X.X] among the diverse
and heterogeneous group of isomerases.14-16
-hydroxycarboxylic acids revealed the
existence of a promising candidate: Lactate racemase
[EC 5.1.2.1].17
The biochemical data on lactate racemase available to
date are somewhat scattered and divers. The respective
enzymatic activity was reported (or assumed) in various
microbial strains in context with their ability to produce
(or degrade) D-lactate through an L-specific lactate pathway. The biodegradation/formation of D-lactate from the
L-isomer via lactate racemase was identified in particular
among (anaerobic) rumen bacteria, such as Megasphaera
elsdenii18,19
-carbonyl enzyme-bound intermediate is still missing. Most important, the biocatalytic racemization of
saturated
-hydroxycarboxylic acids other than lactate
has not been studied to date.28
In search of a suitable racemase activity applicable to
a broad spectrum of substrates encompassing aliphatic
and arylaliphatic
-hydroxycarboxylic acids, which could
not be isomerized with use of mandelate racemase, a
screening was initiated based on the data for lactate
racemase discussed above. Thus, rehydrated (resting)
cells of a representative set of Lactobacilli (20 strains),
Lactococci (9 strains), and halophilic organisms, such as
Halococcus (7 strains) and halobacteria (3 strains, Halobacterium, Haloferax, and Haloarcula), were screened
for their ability to racemize
-hydroxycarboxylic acids in
aqueous buffer at pH 6. To cover a reasonably wide
substrate spectrum, straight-chain, branched, and cyclic
aliphatic
-hydroxycarboxylic acids [(S)-1,2, (R)-3, and
(S)-4-6] were chosen. Special emphasis was put on aryl-alkyl derivatives, such as phenyl-lactates and 4-phenyl-2-hydroxybutanoates [(S)-7-12 and (R)-7,8], since compounds of this type are frequently used as chiral building
blocks for the synthesis of pharmacologically active target
molecules. For instance, (S)-3-cyclohexyl lactate (6) was
found to be an essential component of sialyl LewisX-analogues, which are currently tested as inhibitors of
E-selectin for the treatment of inflammatory disorders.29
(R)-4-Phenyl-2-hydroxybutanoate (8), which has been
prepared by kinetic resolution,30 asymmetric bioreduction,31,32
3-Phenyl lactate (7) and derivatives thereof are frequently used components of pharmaceuticals and natural
antibiotic agents.35,36
logue (12)37 is an integral part of bioactive peptides, such
as Aeruginosins38 and Microcin39 isolated from freshwater
cyanobacteria, which were shown to be potent protease
inhibitors. (R)-p-Fluoro-3-phenyl lactate (9) is a key
building block for the synthesis of AG7088 (Ruprintrivir),
a potent rhinovirus protease inhibitor currently being
tested in clinical trials to treat the common cold.40,41
-hydroxy acid racemizers: On the contrary, Lactobacillus
spp. DSM 20008, DSM 20207, and DSM 20074 had a
desired broad substrate tolerance for all substrates,
including lactate. (iii)
-Hydroxy acid racemizer: Most
remarkably, Lactobacillus sp. DSM 2649 showed broad
activity for nonnatural substrates, in particular 3-phenyl
lactates (7-11), but was unable to racemize lactate.
Scheme 1. Biocatalytic Racemization of
Aliphatic, Arylaliphatic, and Aromatic
-Hydroxycarboxylic Acids (1-14)
|
No clear preference was detectable for Lactobacillus
sakei DSM 20017. In contrast to straight-chain substrates, sterically demanding branched-chain
-hydroxy
acids (4-6) showed reduced racemization rates with all
strains.
To obtain quantitative data on racemization rates, the
course of the racemization of substrates 1-14 was
monitored over time, using Lactobacillus paracasei DSM
20207, which clearly emerged as the "champion" from the
screening (Table 2
). Initial rates were determined from
the constant slope of progress curves at a conversion
below 5%; relative rates were calculated by setting the
racemization rate of the natural substrate (S)-1 as
standard (100%).
In general, straight-chain
-hydroxycarboxylic acids (2,
3) gave better results than bulky branched-chain or
alicyclic analogues (4-6), which can be explained by
steric hindrance. Among the aryl-alkyl derivatives,
phenyl lactate (7) was a better substrate than 2-hydroxy-4-phenylbutanoate (8). p-Halo-substituents on 7 were
tolerated rather well, albeit at slight reduced racemization rates. Low values were obtained for the polar (and
thus heavily hydrated) p-hydroxy analogue 12. (S)-Mandelate (13) and even its sterically demanding o-chloro analogue (14) were converted at fair rates (25%).
Overall, good racemization rates of up to 85% for
aliphatic and up to 59% for arylaliphatic compounds were
achieved, relative to lactate. In addition, the reactions
proved to be essentially clean and less than ~5% of side
products could be detected. It should be noted that
attempts to racemize 7 and 8 under conventional conditions (aq pH 2 to 12, 100
C, 48 h) were unsuccessful.
Close monitoring of the progress of racemization over
time for both enantiomers of substrates 7 and 8 with
Lactobacillus paracasei DSM 20207 revealed that in both
cases, the (R)-enantiomers were racemized more rapidly
than the corresponding (S)-counterparts. Such "nonsymmetric" kinetics are not uncommon for enzyme-catalyzed
racemization reactions.44 Due to the diastereomeric interaction of substrate enantiomers with the chiral (bio)catalyst, the individual KM and kcat values of enantiomers
may differ to a significant extent. However, since these
kinetic effects are opposite, they cancel out with respect
to the overall racemization rate, and as a consequence,
the respective values for the reaction rates of enantiomers
(expressed as kcat/KM) become very similar45-48
In summary, clean biocatalytic racemization of a range
of pharmaceutically important aliphatic, arylaliphatic,
and aromatic
-hydroxycarboxylic acids was accomplished under mild conditions with use of resting cells
of Lactobacillus spp., most noteworthy Lactobacillus
paracasei DSM 20207. The full potential of this novel
biocatalytic activity is currently being explored in
the context of the development of novel deracemization techniques. In addition, the nature of the actual
enzyme(s) involved and the mechanism of action responsible for this racemization is currently being studied in
detail.
General. The following chemicals were purchased. (R)-(+)- and (S)-(-)-lactic acid sodium salt (1), (R)-(+)- and (S)-(-)-2-hydroxybutanoic acid (2), (D)-(-)- and (L)-(+)-3-cyclohexylalanine, (L)-(-)-tyrosine, (R)-(-)-2-hydroxy-3-methylbutanoic acid (4), (D,L)- and (L)-(-)-4-fluoro-, (L)-(-)-4-chloro- and (L)-(-)-4-bromophenylalanine, (S)-(+)-2-hydroxy-3-methylbutanoic acid (4), (R,S)- and (S)-(+)-2-hydroxy-4-methylpentanoic acid (5), (R)-(+)- and (S)-(-)-2-hydroxy-3-phenylhydroxypropanoic acid (7), (R,S)-2-hydroxyhexanoic acid (3) and (S)-mandelic acid (13), (D,L)-4-chloro- and (D,L)-4-bromophenylalanine, (R)-(-)- and (S)-(+)-2-hydroxy-4-phenylbutanoic acid ethyl ester, and (R,S)-2-hydroxy-3-(4-hydroxyphenyl)propanoic acid (12). (R)-o-Chloromandelic acid (14) was a gift from R. Gaisberger (Graz). (S)-2-Hydroxy-3-(4-hydroxyphenyl)propanoic acid (S)-12) was synthesized from L-tyrosine according to ref 39.
Lactobacilli were obtained from the DSMZ (Braunschweig,
Germany), Lactococci were obtained from D. Haltrich (Vienna,
Austria) and BASF AG, respectively, Halobacteria and Halococci were obtained from H. Stan-Lotter (Salzburg) and the
DSMZ, respectively FCC stands for our in-house culture
collection. TLC plates were run on silica gel Merck 60 (F254)
and compounds were visualized by spraying with Mo-reagent
[(NH4)6Mo7O24·4H2O (100 g/L), Ce(SO4)2·4H2O(4 g/L) in H2SO4
(10%)]. Compounds were purified by flash chromatography on
silica gel Merck 60 (230-400 mesh). Optical rotation values
were measured at 589 nm (Na-line) in a 1dm cuvette and are
given in units of 10 deg cm2 g-1. NMR spectra were recorded
in CDCl3 360 (1H) and 90 (13C) MHz. Chemical shifts are
reported in ppm relative to TMS (
0.00) as internal standard,
and coupling constants (J) are given in Hz. The degree of
conversion (expressed as % of racemization with 100% corresponding to the racemate) and enantiomeric excesses were
determined via GC or HPLC on a chiral stationary phase.
HPLC analyses were carried out with a Chiralpak AD column
(column A, Daicel, 0.46 cm × 25 cm). GC analyses were
performed with a CP-Chirasil-DEX CB column (column B, 25
m, 0.32 mm, 0.25
m film) or an Astec Chiraldex B-TA (column
C, 30 m, 0.25 mm). H2 was used as carrier gas.
Strains. The following strains showed racemization-activity toward one or more substrates: Lactobacillus paracasei DSM 20008, DSM 20207, DSM 2649, Lactobacillus sakei DSM 20017, Lactobacillus halotolerans DSM 20190, Lactobacillus delbrueckii DSM 20074, Lactobacillus brevis DSM 20054, Lactobacillus acetotolerans DSM 20749, Lactobacillus oris DSM 4864.
No racemization activity was found in the following strains: Haloferax volcanii DSM 5716, Haloarcula vallismortis DSM 3756, Lactobacillus acidophilus DSM 20079, Lactobacillus piscicola DSM 20722, Lactobacillus confusus DSM 20196, Lactobacillus farciminis DSM 20184, Lactobacillus gasseri DSM 20243, Lactobacillus alimentarius DSM 20249, Lactobacillus jensenii DSM 20557, Lactobacillus kandleri DSM 20593, Lactobacillus fructosus DSM 20349, Halococcus morrhuae DSM 1307, Halococcus saccharolyticus DSM 5350, Halococcus dombrowskii DSM 14522, Halobacterium salinarum DSM 3754, Halobacterium sp. NRC-1 ATCC 700922, Halococcus salifodinae DSM 8989, Halobacterium sp. A FCC 086, Lactococcus lactis sp. Cremoris DSM 20388, Lactococcus lactis sp. Cremoris DSM 20069, Lactococcus lactis DSM 20729, Lactococcus lactis DSM 20481, and Lactococcus FCC 093, FCC 094, FCC 095, FCC 096, FCC 097.
FCC numbers refer to our in-house culture collection.
Medium for Active Strains. Lactobacillus paracasei DSM 20008, DSM 20207, DSM 2649, Lactobacillus sakei DSM 20017, Lactobacillus halotolerans DSM 20190, Lactobacillus delbrueckii DSM 20074, Lactobacillus brevis DSM 20054, and Lactobacillus oris DSM 4864 were grown on medium #11 as suggested by DSMZ. The following components of the medium were sterilized in five separate groups: Group I: Pepticase (10 g/L, Sigma), bacteriological peptone (10 g/L, Oxoid), yeast extract (5 g/L, Oxoid). Group II: Glucose (20 g/L, Fluka). Group III: Tween 80 (polyoxyethylene-sorbitan-monooleate, 1 g/L, Aldrich), Group IV: K2HPO4 (2 g/L, Merck). Group V: Na-acetate trihydrate (8.3 g/L, Fluka), (NH4)2-citrate (2 g/L, Fluka), MgSO4·7H2O (0.20 g/L, Fluka), MnSO4 (0.05 g/L, Fluka). Lactobacillus acetotolerans DSM 20749 was grown in medium DSMZ #231, which is identical with medium DSMZ #11 with adjustment of the pH value to pH 5.2.
Strain Maintenance. Lactobacilli were maintained on
agar plates, using the above-described media with the addition
of agar (20 g/L). Subculturing was performed every 4 weeks,
the plates were left in the incubator for 48 h at 30
C, and
long-term storage was at +4
C. It should be noted that a
strong loss of activity was observed when the cells were frozen,
even in the presence of cryo-protectants, such as (i) NaCl
(0.7%) and DMSO (20%) or (ii) glycerol/water (95:5 or 1:1).
Growth of Microorganisms. Strains were grown in flask
cultures without shaking at 30
C (Lactobacillus paracasei
DSM 20008, DSM 20207, DSM 2649, Lactobacillus sakei DSM
20017, Lactobacillus halotolerans DSM 20190, Lactobacillus
brevis DSM 20054, and Lactobacillus acetotolerans DSM
20749) and at 37
C (Lactobacillus delbrueckii DSM 20074 and
Lactobacillus oris DSM 4864). After transfer from agar plates,
the microorganisms were grown for 3 d (Lactobacillus sakei
DSM 20017, Lactobacillus paracasei DSM 20008, DSM 20207,
DSM 2649, Lactobacillus halotolerans DSM 20190, Lactobacillus brevis DSM 20054, Lactobacillus oris DSM 4864, Lactobacillus delbrueckii DSM 20074) and for 11 d (Lactobacillus
acetotolerans DSM 20749). Then the cells were harvested by
centrifugation (18 000 × g), washed twice with BIS-TRIS
buffer (50 mM, 10-2 M MgCl2, pH 6), lyophilized, and stored
at +4
C.
General Screening Procedure for Biocatalytic Racemization. For the screening, 50 mg of whole lyophilized cells
was rehydrated in 0.5 mL of aqueous BIS-TRIS buffer (50 mM,
10-2 M MgCl2, pH 6) for 1 h at 42
C with shaking at 150 rpm.
Substrate (5 mg) was added followed by shaking of the reaction
mixture with 150 rpm at 42
C for 24 h. Then the reaction
mixture was acidified with 2 M HCl (1 drop) and the cells were
removed by centrifugation. The supernatant was extracted
with Et2O and the organic phase was dried with Na2SO4. The
determination of conversion and enantiomeric excess was
carried out by GC or HPLC on a chiral stationary phase. For
HPLC determination, the organic phase was evaporated under
reduced pressure and the residue was dissolved in HPLC
eluent (without trifluoroacetic acid).
This study was performed in cooperation with BASF AG (Ludwigshafen) within the Competence Center Applied Biocatalysis and financial support from the FFG, the City of Graz, the Province of Styria, and BASF AG is gratefully acknowledged. R. Gaisberger (Graz) and Ciba Specialty Chemicals (Basel) are thanked for the generous supply with chiral materials. D. Haltrich (Vienna) and H. Stan-Lotter (Salzburg) are thanked for the generous donation of Lactococci and Halococci, respectively.
Synthesis of substrates and reference materials and procedures for GC and HPLC analyses and retention times. This material is available free of charge via the Internet at http://pubs.acs.org.
* In papers with more than one author, the asterisk indicates the name of the author to whom inquiries about the paper should be addressed.
University of Graz.
BASF-AG.
Research Centre Applied Biocatalysis, Graz, Austria.
1. Eliel, E. L.; Wilen, S. H.; Doyle, M. P. Basic Organic Stereochemistry; Wiley: New York, 2001; pp 277-278.
2. Ebbers, E. J.; Ariaans, G. J. A.; Houbiers, J. P. M.; Bruggink,
A.; Zwanenburg, B. Tetrahedron 1997, 53, 9417.![]()
3. Faber, K. Chem. Eur. J. 2001, 7, 5004.![]()
4. Pamies, O.; Bäckvall, J.-E. Chem. Rev. 2003, 103, 3247.![]()
5. Pellissier, H. Tetrahedron 2003, 59, 8291.![]()
6. Pamies, O.; Bäckvall, J.-E. Chem. Rev. 2003, 103, 3247.![]()
7. Kim, M.-J.; Ahn, Y.; Park, J. Curr. Opinion Biotechnol. 2002,
13, 578.![]()
8. El Gihani, M. T.; Williams, J. M. J. Curr. Opinion Chem. Biol.
1999, 3, 11.![]()
9. Schnell, B.; Faber, K.; Kroutil, W. Adv. Synth. Catal. 2003, 345,
653.![]()
10. Strauss, U. T.; Faber, K. Tetrahedron: Asymmetry 1999, 10,
4079.![]()
11. Felfer, U.; Strauss, U. T.; Kroutil, W.; Fabian, W. M. F.; Faber,
K. J. Mol. Catal. B: Enzym. 2001, 15, 213.![]()
12. Powers, V. M.; Koo, C. W.; Kenyon, G. L.; Gerlt, J. A.; Kozarich,
J. W. Biochemistry 1991, 30, 9255.
Prat-Resina, X.; Garcia-Viloca, M.;
Gonzalez-Lafont, A.; Lluch, J. M. ChemPhysChem 2002, 4, 5365.![]()
13. For a review on the substrate tolerance of mandelate racemase and a general substrate model see: Felfer, U.; Goriup, M.; Koegl, M.; Wagner, U.; Faber, K.; Kroutil, W. Adv. Synth. Catal. Submitted for publication.
14. Adams, E. Adv. Enzymol. Relat. Areas Mol. Biol. 1976, 44, 69.
15. Glaser, L. The Enzymes 1972, 6, 355.![]()
16. Tanner, M. E. Acc. Chem. Res. 2002, 35, 237.![]()
17. Synonyms for lactate racemase are lacticoracemase, hydroxy acid racemase, and lactic acid racemase. No sequence or X-ray structure for lactate racemase or hydroxy acid racemase is available to date. www.Brenda.Uni-Koeln.de.
18. Hino, T.; Kuroda, S. Appl. Environ. Microbiol. 1993, 59, 255.![]()
19. Hino, T.; Shimada, K.; Maruyama, T. Appl. Environ. Microbiol.
1994, 60, 1827.![]()
20. Melville, S. B.; Michel, T. A.; Macy, J. M. FEMS Microbiol. Lett.
1987, 40, 289.![]()
21. Stockland, A. E.; San Clemente, C. L. J. Bacteriol. 1969, 100,
347.![]()
22. Malleret, C.; Lauret, R.; Ehrlich, S. D.; Morel-Deville, F.;
Zagorec, M. Microbiology 1998, 144, 3327.![]()
23. No lactate racemase activity was found in Lactobacillus casei
NRRL-B445 and L. delbrueckii ATCC 11842, see: Hjörleifsdottir, S.;
Seevaratnam, S.; Holst, O.; Mattiasson, B. Curr. Microbiol. 1990, 20,
287.![]()
24. Oren, A.; Gurevich, P.; Silverman, A. Can. J. Microbiol. 1995,
41, 302.![]()
25. Cantwell, A.; Dennis, D. Biochemistry 1974, 13, 287.
Pepple,
J. S.; Dennis, D. Biochim. Biophys. Acta 1976, 429, 1036.![]()
26. Hiyama, T.; Fukui, S.; Kitahara, K. J. Biochem. 1968, 64, 99.
27. Stetter, K. O.; Kandler, O. Arch. Microbiol. 1973, 94, 221.![]()
28. For a preliminary communication see: Glueck, S. M.; Larissegger-Schnell, B.; Csar, K.; Kroutil, W.; Faber, K. Chem. Commun.
2005, 1904.![]()
29. Storz, T.; Dittmar, P.; Fauquez, P. F.; Marschal, P.; Lottenbach,
W. U.; Steiner, H. Org. Proc. Res. Dev. 2003, 7, 559.![]()
30. Liese, A.; Kragl, U.; Kierkels, H.; Schulze, B. Enzyme Microb.
Technol. 2002, 30, 673.![]()
31. Schmidt, E.; Blaser, H.-U.; Fauquex, P. F.; Sedelmeier, G.; Spindler, F. In Microbial Reagents in Organic Synthesis; Servi, S., Ed.; Kluwer: Dordrecht, The Netherlands 1992; pp 377-388.
32. Oda, S.; Inada, Y.; Kobayashi, A.; Ohta, H. Biosci. Biotechnol.
Biochem. 1998, 62, 1762.![]()
33. Chadha, A.; Baskar, B. Tetrahedron: Asymmetry 2002, 13, 1461.
34. Blaser, H.-U.; Burkhardt, S.; Kirner, H. J.; Mössner, T.; Studer,
M. Synthesis 2003, 1679.![]()
35. For antifungal activity see: Ström, K.; Sjögren, J.; Broberg, A.;
Schnürer, J. Appl. Environ. Microbiol. 2002, 68, 4322.![]()
36. For anti-Listeria activity see: Dieuleveux, V.; van der Pyl, D.;
Chataud, J.; Gueguen, M. Appl. Environ. Microbiol. 1998, 64, 800.![]()
37. Lawrence, N. J.; Brown, S. Tetrahedron 2002, 58, 613.![]()
38. Valls, N.; Lopez-Canet, M.; Vallribere, M.; Bonjoch, J. Chem.
Eur. J. 2001, 7, 3446.
Valls, N.; Vallribera, M.; Carmeli, S.; Bonjoch,
J. Org. Lett. 2003, 5, 447.
Ishida, K.; Okita, Y.; Matsuda, H.; Okino,
T.; Murakami, M. Tetrahedron 1999, 55, 10971.![]()
39. Valls, N.; Vallribera, M.; Lopez-Canet, M.; Bonjoch, J. J. Org.
Chem. 2002, 67, 4945.![]()
40. Tao, J.; McGee, K. Org. Proc. Res. Dev. 2002, 6, 520.![]()
41. Dragovich, P. S.; Prins, T. J.; Zhou, R.; Brown, E. L.; Maldonado,
F. C.; Fuhrman, S. A.; Zalman, L. S.; Tuntland, T.; Lee, C. A.; Patick,
A. K.; Matthews, D. A.; Hendrickson, T. F.; Kosa, M. B.; Liu, B.; Batugo,
M. R.; Gleeson, J.-P. R.; Sakata, S. K.; Chen, L.; Guzman, M. C.;
Meador, J. W.; Ferre, R. A.; Worland, S. T. J. Med. Chem. 2002, 45,
1607.![]()
42. van Langen, L. M.; van Rantwijk, F.; Sheldon, R. A. Org. Proc.
Res. Dev. 2003, 7, 828.
43. Feliste, R.; Delebassee, D.; Simon, M. F.; Chap, H.; Derfreyn,
G.; Vallee, E.; Douste-Blazy, L.; Maffrand, J. P. Thromb. Res. 1987,
48, 403.![]()
44. For an interesting example of an "overshoot"-reaction observed
in the enzymatic racemization of D- and L-alanine using a bacterial
pyridoxyl-dependent alanine racemase see: Spies, M. A.; Woodward,
J. J.; Watnik, M. R.; Toney, M. D. J. Am. Chem. Soc. 2004, 126, 7464.
45. Shibata, K.; Shirasuna, K.; Motegi, K.; Kera, Y.; Abe, H.;
Yamada, R. Comp. Biochem. Physiol. B 2000, 126, 599.![]()
46. Watanabe, A.; Yoshimura, T.; Lim, Y. H.; Kurokawa, Y.; Soda,
K.; Esaki, N. J. Mol. Catal. B: Enzymol. 2001, 12, 145.![]()
47. Weil-Malherbe, H. Biochem. J. 1966, 101, 169.![]()
48. Verseck, S.; Bommarius, A.; Kula, M.-R. Appl. Microbiol.
Biotechnol. 2001, 55, 354.![]()
49. Yamada, M.; Furuhashi, K. J. Biochem. 1968, 63, 59.![]()
50. Hiyama, T.; Fukui, S.; Kitahara, K. J. Biochem. 1968, 64, 99.
|
strain |
|||||||||
|
substrate |
R |
Lactobacillus halotolerans DSM 20190 |
Lactobacillus brevis DSM 20054 |
Lactobacillus acetotolerans DSM 20749 |
Lactobacillus paracasei DSM 20008 |
Lactobacillus paracasei DSM 20207 |
Lactobacillus delbrueckii DSM 20074 |
Lactobacillus paracasei DSM 2649 |
Lactobacillus sakei DSM 20017 |
|
(S)-1 |
CH3- |
++ |
++ |
++ |
++ |
++ |
++ |
- |
+ |
|
(S)-2 |
CH3-CH2- |
+ |
- |
- |
+ |
++ |
- |
+ |
- |
|
(R)-3 |
CH3-(CH2)3- |
+ |
n.d. |
n.d. |
++ |
++ |
++ |
++ |
- |
|
(S)-4 |
(CH3)2CH- |
- |
- |
- |
- |
± |
- |
- |
- |
|
(S)-5 |
(CH3)2CH-CH2- |
± |
- |
- |
± |
± |
± |
± |
± |
|
(S)-6 |
c-C6H11-CH2- |
- |
- |
- |
+ |
+ |
- |
± |
+ |
|
(S)-7 |
C6H5-CH2- |
- |
- |
+ |
++ |
++ |
++ |
+ |
± |
|
(S)-8 |
C6H5-(CH2)2- |
+ |
± |
+ |
++ |
++ |
++ |
++ |
± |
|
(S)-9 |
p-F-C6H4-CH2- |
- |
- |
- |
++ |
++ |
++ |
++ |
n.d. |
|
(S)-10 |
p-Cl-C6H4-CH2- |
n.d. |
n.d. |
n.d. |
+ |
++ |
+ |
++ |
n.d. |
|
(S)-11 |
p-Br-C6H4-CH2- |
n.d. |
n.d. |
n.d. |
+ |
++ |
± |
++ |
n.d. |
|
(S)-12 |
p-OH-C6H4-CH2- |
± |
- |
- |
+ |
++ |
++ |
- |
- |
|
(S)-13 |
C6H5- |
- |
- |
- |
± |
+ |
- |
- |
- |
|
(R)-14 |
o-Cl-C6H4- |
- |
- |
- |
± |
+ |
+ |
± |
± |
a n.d. = not determined; (-) = no racemization; (±) = slow racemization (conversion
20%); (+) = moderate racemization (conversion
20-70%); (++) = fast racemization (conversion
70%); 100% conversion corresponds to complete racemization under standard conditions
(i.e., ee = 0%, see the Experimental Section).
|
substrate |
R |
rel rate [%] |
|
(S)-1 |
CH3- |
100 |
|
(S)-2 |
CH3-CH2- |
85 |
|
(R)-3 |
CH3-(CH2)3- |
80 |
|
(S)-4 |
(CH3)2CH- |
2 |
|
(S)-5 |
(CH3)2CH-CH2- |
1.5 |
|
(S)-6 |
c-C6H11-CH2- |
3a |
|
(R)-7 |
C6H5-CH2- |
59 |
|
(S)-7 |
C6H5-CH2- |
21 |
|
(R)-8 |
C6H5-(CH2)2- |
47 |
|
(S)-8 |
C6H5-(CH2)2- |
35 |
|
(S)-9 |
p-F-C6H4-CH2- |
19 |
|
(S)-10 |
p-Cl-C6H4-CH2- |
22 |
|
(S)-11 |
p-Br-C6H4-CH2- |
27 |
|
(S)-12 |
p-HO-C6H4-CH2- |
8 |
|
(S)-13 |
C6H5- |
25 |
|
(R)-14 |
o-Cl-C6H4- |
24 |
a Strain DSM 20008 was used.